Primary retroperitoneal lymph node dissection in clinical stage 2a/b non‐seminomatous germ cell tumour
Our study suggests considering primary RPLND not only in marker-negative CS 2a but also in CS 2b. Further research should determine the efficacy of primary RPLND in men with CS 2c and marker-positive CS 2, as well as which patients may benefit from adjuvant chemotherapy and the optimal cycle number.
Authors
- Sean P. Stroup (ORCID: https://orcid.org/0000-0003-1508-9012)
- Matthew Ho (ORCID: https://orcid.org/0000-0001-7937-1557)
- Nicholas R. Rocco
- Walter Cazzaniga (ORCID: https://orcid.org/0000-0002-0372-5694)
- Sebastiano Nazzani (ORCID: https://orcid.org/0000-0001-5945-3248)
- Alireza Ghoreifi (ORCID: https://orcid.org/0000-0002-7368-7240)
- Nicolas Branger (ORCID: https://orcid.org/0000-0001-7024-7322)
- Zhiyu Qian
- Wade J. Sexton (ORCID: https://orcid.org/0000-0002-1176-0369)
- Clint Cary
- Timothy N. Clinton
- Christian D. Fankhauser (ORCID: https://orcid.org/0000-0002-4073-5488)
- Nirmish Singla (ORCID: https://orcid.org/0000-0001-9495-6983)
- James Porter (ORCID: https://orcid.org/0000-0001-9275-4552)
- Kathleen Olson
- Angelika Terbuch (ORCID: https://orcid.org/0000-0003-2918-1370)
- Anirudh Yerrapragada (ORCID: https://orcid.org/0000-0002-4150-6548)
- Hooman Djaladat (ORCID: https://orcid.org/0000-0002-1984-3556)
- Siamak Daneshmand (ORCID: https://orcid.org/0000-0001-6224-9598)
- Axel Heidenreich (ORCID: https://orcid.org/0000-0002-2511-3664)
- Fady Baky
- Armon Amini (ORCID: https://orcid.org/0000-0002-8991-3708)
- Scott E. Eggener (ORCID: https://orcid.org/0000-0001-6677-2503)
- Pia Paffenholz (ORCID: https://orcid.org/0000-0002-8209-7795)
- Aditya Bagrodia (ORCID: https://orcid.org/0000-0002-3358-1193)
- Nicola Nicolai (ORCID: https://orcid.org/0000-0002-5718-2699)
- David Nicol (ORCID: https://orcid.org/0000-0002-5623-7467)
- Robert J. Hamilton (ORCID: https://orcid.org/0000-0002-6715-5934)
- Isamu Tachibana (ORCID: https://orcid.org/0000-0002-0950-1296)
- Luca Antonelli (ORCID: https://orcid.org/0000-0001-6067-5497)
Institutions
- University of Southern California (US)
- Brigham and Women's Hospital (US)
- Naval Medical Center San Diego (US)
- Royal Marsden NHS Foundation Trust (GB)
- Institute of Cancer Research (GB)
- Johns Hopkins University (US)
- University of Lucerne (CH)
- University of Cologne (DE)
- University of Toronto (CA)
- University of Washington (US)
- Medical University of Graz (AT)
- University of Zurich (CH)
- Johns Hopkins Medicine (US)
- Policlinico Umberto I (IT)
- Moffitt Cancer Center (US)
- University of California San Diego (US)
- University of Chicago Medical Center (US)
- Luzerner Kantonsspital (CH)
- Mayo Clinic in Arizona (US)
- Institut Paoli-Calmettes (FR)
- University Hospital Cologne (DE)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- Medical University of Vienna (AT)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1111/bju.16618
- Citations
- 2
- Primary Topic
- Testicular diseases and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.15